Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Registration Number
- NCT05934526
- Lead Sponsor
- GB002, Inc.
- Brief Summary
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 350
-
Adult subjects aged 18 to 75 years.
-
Body mass index (BMI) ≥ 15 kg/m^2 and ≤ 40 kg/m^2.
-
Diagnosis of PAH classified by one of the following:
- Idiopathic PAH (IPAH) or heritable PAH (HPAH).
- PAH associated with connective tissue disease (CTD-APAH); PAH associated with anorexigen or PAH associated with methamphetamine use.
- Congenital heart disease with simple systemic to pulmonary shunt at least 1 year after surgical repair.
-
6MWDs ≥ 150 meters and ≤ 475 meters during Screening prior to randomization.
-
WHO FC II or III.
-
US Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) Lite 2 Risk Score ≥ 5 OR NT-proBNP ≥ 300 ng/L OR PVR ≥ 800 dyne s/cm^5.
-
Cardiac catheterization within the screening period, or a standard of care right heart catheterization (RHC) (with pressure wave forms available for review) up to 48 weeks prior to Screening.
- Mean pulmonary arterial pressure (mPAP) > 20 mmHg (at rest), AND
- Pulmonary vascular resistance (PVR) ≥ 400 dyne·s/cm^5, AND
- Pulmonary capillary wedge pressure (PCWP) or left ventricle end-diastolic pressure (LVEDP) ≤ 15 mmHg.
-
Treatment with at least one allowed background PAH disease-specific medication prior to Screening.
- Subjects receiving treatment with endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, guanylate cyclase stimulators, and/or prostacyclin analogues or prostacyclin receptor agonists are eligible only if on a stable dose for at least 12 weeks prior to and throughout Screening.
- Subjects receiving treatment with sotatercept are eligible only if on a stable dose of sotatercept for at least 24 weeks prior to and throughout Screening, with a RHC performed during Screening (or within 2 weeks prior to Screening).
-
Pulmonary function tests (PFTs) at Screening or completed no more than 12 weeks prior to Screening.
-
Women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening and on Day 1 before first administration of Investigational Product (IP).
-
WOCBP who are not abstinent and intend to be sexually active with a non-sterilized male partner must be willing to use a highly effective method of contraception from consent through 30 days following the last administration of IP.
-
Male subjects: Non-sterilized male subjects who are not abstinent and intend to be sexually active with a female partner of childbearing potential must use a male condom from consent through 90 days after the last dose of IP.
-
Evidence of chronic thromboembolic disease or acute pulmonary embolism.
-
Uncontrolled systemic hypertension as evidenced by systolic blood pressure > 160 mm Hg or diastolic blood pressure > 100 mm Hg.
-
Systolic blood pressure < 90 mm Hg during Screening.
-
WHO Pulmonary Hypertension Group 2 - 5.
-
Human immunodeficiency virus (HIV)-associated PAH, schistosomiasis associated PAH, PAH associated with portal hypertension, or pulmonary veno-occlusive disease (PVOD).
-
Recent history of left-sided heart disease and/or clinically significant cardiac disease within 48 weeks of Screening.
-
Left ventricular ejection fraction (LVEF) ≤ 50% within 24 weeks of Screening.
-
Hemodynamically significant valvular heart disease or uncontrolled symptomatic coronary disease.
-
History of atrial septostomy.
-
Uncontrolled atrial fibrillation or paroxysmal atrial fibrillation.
-
Untreated severe obstructive sleep apnea.
-
Hepatic dysfunction defined as Child-Pugh Class A or higher, or as evidenced by one of the following at Screening: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 x upper limit of normal (ULN) or total bilirubin ≥ 1.5 x ULN.
-
Severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or IP administration (eg, history of intracranial hemorrhage, recurrent syncope).
-
Any musculoskeletal disease, injury, or any other disease that limits evaluation of 6MWT.
-
Initiation of an exercise program for cardiopulmonary rehabilitation within 12 weeks prior to Screening or planned during the study.
-
Pregnant or nursing or intends to become pregnant during the duration of the study.
-
Body weight < 37 kg at Screening.
-
Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m^2 Hemoglobin (Hgb) concentration < 8.5 g/dL at Screening.
-
Evidence of active or latent Human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C, or tuberculosis (TB) infection at Screening.
-
Prior/concurrent treatment with tyrosine kinase inhibitors or activin signaling inhibitors:
- Tyrosine kinase inhibitors, other than Janus kinase inhibitors approved for systemic autoimmune rheumatic diseases, within 12 weeks prior to Screening.
- Activin signaling inhibitors within 5 half-lives prior to Screening.
-
Requirement of IV inotropes (ie, levosimendan, dopamine, dobutamine, milrinone, norepinephrine) or IV diuretics for more than 24 hours within 4 weeks prior to Screening.
-
Subjects currently receiving oral anticoagulants (ie, warfarin/other vitamin K antagonists or direct-acting oral anticoagulants [DOACs]) if any of the following criteria are met:
a. History within 24 weeks of Screening of: i. Syncope, or ii. Symptomatic bleeding in a critical area or organ iii. Intramuscular with compartment syndrome, or iv. Bleeding causing a fall in hemoglobin levels of 1.24 mmol/L (20 g/L or greater) or more, or v. Bleeding leading to a transfusion of 2 U or more of whole blood or red blood cells.
b. History of central nervous system pathology.
c. History of clinically significant (massive) hemoptysis.
d. If on warfarin/other vitamin K antagonist, uncontrolled International normalized ratio (eg, INR > 3) as assessed.
e. Platelet count < 150 x 10^9/L at Screening.
f. Concomitant use of antiplatelet agents.
g. CTD-APAH
h. Concomitant use of sotatercept.
-
Prior participation in seralutinib studies and/or prior treatment with seralutinib.
-
Currently participating in or has participated in a study of an investigational agent or has used an investigational device for the treatment of PAH within 12 weeks or 5 half-lives of the investigational agent, whichever is longer, prior to Screening.
-
Current use of inhaled tobacco- or nicotine-containing products (including e-vapor products) and/or inhaled marijuana.
-
Current alcohol use disorder based on the opinion of the Investigator, and/or a positive test for drugs of abuse.
-
Subjects with a history of severe milk protein allergy or known intolerance to lactose.
-
QT interval corrected for heart rate using Fridericia's formula (QTcF) of > 500 msec.
-
Have any other condition or reason that, in the opinion of the Investigator or in the opinion of the Sponsor's Medical Monitor (MM) (or designee) in consultation with the Investigator, would prohibit the subject from participating in the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Generic Dry Powder Inhaler Placebo inhaled orally twice daily (BID) up to 48 weeks Seralutinib 90 mg Generic Dry Powder Inhaler Seralutinib inhaled orally BID up to 48 weeks Placebo Placebo Placebo inhaled orally twice daily (BID) up to 48 weeks Seralutinib 90 mg Seralutinib Seralutinib inhaled orally BID up to 48 weeks
- Primary Outcome Measures
Name Time Method Change in distance achieved on the six-minute walk test (6MWT), six-minute walk distance (Δ6MWD) from baseline to Week 24 Baseline to 24 weeks
- Secondary Outcome Measures
Name Time Method Change in NT-proBNP from baseline to Week 24 Baseline to 24 weeks Proportion of subjects with each of the Clinical Worsening Outcomes: Baseline to 52 weeks 1. Death (all causes)
2. Hospitalization for signs and symptoms of worsening PAH (≥ 24 hours)
3. Worsening-related listing for or receipt of lung and/or heart/lung transplantation
4. Atrial septostomy performed
5. Worsening PAH requiring initiation of therapy with an additional approved background PAH disease-specific medication or the need to increase the dose of parenteral (IV or subcutaneous infusion) prostacyclin by 10% or more
6. Disease progression, defined by both of the following events occurring at any time, even if they began at different times, as compared to their baseline values:
1. Decrease in 6MWD of ≥ 15% on two consecutive tests, performed a minimum of 4 hours but no more than 1 week apart AND
2. Worsened WHO FCTime to first event of Clinical Worsening from first dose of Investigational Product (IP) through end of study Baseline to 48 weeks Proportion of subjects who improve from baseline in WHO FC or maintain WHO FC II Baseline to 24 weeks Change in PAH-SYMPACT™ from baseline to Week 24 Baseline to 24 weeks Incidence of treatment-emergent adverse events (TEAEs), serious TEAEs (SAEs), and treatment-emergent adverse events of special interest (AESIs) Baseline to 52 weeks Proportion of subjects who achieve all of the following components of clinical improvement at Week 24, in the absence of clinical worsening: Baseline to 24 weeks 1. Improvement from baseline in World Health Organization (WHO) functional class (FC) or maintenance of WHO FC II
2. Decrease from baseline in N-terminal pro b-type natriuretic peptide (NT-proBNP) of ≥ 30% or decrease and maintenance at \< 300 ng/L
3. Increase from baseline in 6MWD of ≥ 10% or ≥ 30 mProportion of subjects with ≥ 1 point decrease from baseline in US Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) Lite 2 Risk Score at Week 24 Baseline to 24 weeks Change in Euro-QoL - 5 Dimensions - 5 Levels (EQ-5D-5L) from baseline to Week 24 Baseline to 24 weeks
Trial Locations
- Locations (185)
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Valley Advanced Lung Diseases Institute
🇺🇸Fresno, California, United States
Keck Medical Center of USC
🇺🇸Los Angeles, California, United States
Dept of Veterans Affairs Greater Los Angeles Healthcare System
🇺🇸Los Angeles, California, United States
University of California, Irvine Medical Center
🇺🇸Orange, California, United States
UC Davis Health
🇺🇸Sacramento, California, United States
Medical Corporation
🇺🇸Santa Barbara, California, United States
Stanford Healthcare
🇺🇸Stanford, California, United States
University of Colorado Hospital
🇺🇸Aurora, Colorado, United States
UConn Health/Clinical Research Center
🇺🇸Farmington, Connecticut, United States
Winchester Center for Lung Disease
🇺🇸New Haven, Connecticut, United States
The George Washington University Medical Faculty Associates
🇺🇸Washington, District of Columbia, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead
🇺🇸Atlanta, Georgia, United States
Emory University
🇺🇸Atlanta, Georgia, United States
Northside Hospital Laboratory - Atlanta
🇺🇸Atlanta, Georgia, United States
Northwestern Memorial Hospital, Clinical Research Unit
🇺🇸Chicago, Illinois, United States
UI Health Hospital
🇺🇸Chicago, Illinois, United States
University of Iowa Hospitals & Clinics
🇺🇸Iowa City, Iowa, United States
University of Kansas Medical Center
🇺🇸Kansas City, Kansas, United States
Norton Hospital
🇺🇸Louisville, Kentucky, United States
Ochsner Medical Center
🇺🇸New Orleans, Louisiana, United States
University of Maryland Medical Center
🇺🇸Baltimore, Maryland, United States
Tufts Medical Center
🇺🇸Boston, Massachusetts, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
M Health Fairview University of Minnesota Medical Center - East Bank
🇺🇸Minneapolis, Minnesota, United States
University of Missouri
🇺🇸Columbia, Missouri, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
University of New Mexico Health Sciences Center
🇺🇸Albuquerque, New Mexico, United States
NYU Langone Health
🇺🇸New York, New York, United States
University of Rochester Medical Center
🇺🇸Rochester, New York, United States
UNC Hospitals
🇺🇸Chapel Hill, North Carolina, United States
Duke University Medical Center - Duke South
🇺🇸Durham, North Carolina, United States
University of Cincinnati Medical Center
🇺🇸Cincinnati, Ohio, United States
Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
The Ohio State University Wexner Medical Center
🇺🇸Columbus, Ohio, United States
INTEGRIS Cardiovascular Physicians, LLC
🇺🇸Oklahoma City, Oklahoma, United States
Oregon Health & Science University
🇺🇸Portland, Oregon, United States
The Hospital of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Temple Heart and Vascular Institute (Outpatient Clinic)
🇺🇸Philadelphia, Pennsylvania, United States
Allegheny General Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
UPMC Presbyterian Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
Rhode Island Hospital
🇺🇸Providence, Rhode Island, United States
Medical University of South Carolina - Nexus Research Center
🇺🇸Charleston, South Carolina, United States
Baylor University Medical Center
🇺🇸Dallas, Texas, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
CHI St. Luke's Health Baylor College of Medicine Medical Center
🇺🇸Houston, Texas, United States
Houston Methodist Outpatient Center
🇺🇸Houston, Texas, United States
Baylor Scott & White Medical Center - The Heart Hospital
🇺🇸Plano, Texas, United States
University of Texas Health Science Center at San Antonio
🇺🇸San Antonio, Texas, United States
Intermountain Medical Center
🇺🇸Murray, Utah, United States
Inova Fairfax Medical Campus
🇺🇸Falls Church, Virginia, United States
Pulmonary Associates of Richmond, Inc.
🇺🇸Richmond, Virginia, United States
Advocate Aurora Health-Aurora St. Luke's Medical Center
🇺🇸Milwaukee, Wisconsin, United States
Froedtert Hospital/Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
Cardiologia Palermo
🇦🇷Buenos Aires, Argentina
Instituto Cardiovascular de Buenos Aires
🇦🇷Buenos Aires, Argentina
Instituto de Cardiologia de Corrientes Juana Francisca Cabral
🇦🇷Corrientes, Argentina
Hospital Privado Centro Medico de Cordóba S.A.
🇦🇷Córdoba, Argentina
Instituto de Investigaciones Clinicas Quilmes
🇦🇷Quilmes, Argentina
Sanatorio Parque S.A.
🇦🇷Rosario, Argentina
Instituto Medico Rio Cuarto
🇦🇷Río Cuarto, Argentina
Hospital Provincial Dr. José María Cullen
🇦🇷Santa Fe, Argentina
Macquarie University
🇦🇺North Ryde, New South Wales, Australia
St Vincent's Hospital
🇦🇺Melbourne, Victoria, Australia
Wesley Research Institute
🇦🇺Auchenflower, Australia
Royal Hobart Hospital
🇦🇺Hobart, Australia
Nepean Hospital
🇦🇺Kingswood, Australia
Religious Hospital Linz GmbH
🇦🇹Linz, Austria
AKH-Vienna Medical Univesity of Vienna Internal Medicine II-Cardiology
🇦🇹Vienna, Austria
Hôpital Erasme
🇧🇪Anderlecht, Belgium
University Hospitals of Leuven (Campus Gasthuisberg)
🇧🇪Leuven, Belgium
Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa
🇧🇷Belo Horizonte, Brazil
Complexo de Prevencao, Diagnostico, Terapia e Reabilitacao Respiratoria - Hospital Dia do Pulmao
🇧🇷Blumenau, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre
🇧🇷Porto Alegre, Brazil
Uniao Brasileira de Educaçao e Assistência Hospital São Lucas da PUCRS
🇧🇷Porto Alegre, Brazil
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
🇧🇷São Paulo, Brazil
Núcleo de Gestão de Pesquisa/Hospital São Paulo - SPDM/UNIFESP
🇧🇷São Paulo, Brazil
London Health Science Centre - Victoria Hospital
🇨🇦London, Ontario, Canada
University of Ottawa Heart Institute
🇨🇦Ottawa, Ontario, Canada
Peter Lougheed Center
🇨🇦Calgary, Canada
University Health Network
🇨🇦Toronto, Canada
Enroll SpA
🇨🇱Santiago, Region Metropolitana, Chile
Centro de Investigacion Clinica UC-CICUC
🇨🇱Santiago, Chile
Fundación Abood Shaio
🇨🇴Bogotá, Colombia
Fundación Neumologica Colombiana
🇨🇴Bogotá, Colombia
Institut Klinicke a Experimentalni Mediciny
🇨🇿Praha, Czechia
Všeobecná fakultní nemocnice v Praze Il. interní klinika kardiologie a angiologie VFN a 1.LF UK Centrum pro plicní hypertenzi
🇨🇿Praha, Czechia
Aarhus Universitetshospital, Department of Cardiology
🇩🇰Aarhus, Denmark
Rigshospitalet, Department of Cardiology
🇩🇰Copenhagen, Denmark
CHU Bicêtre
🇫🇷Le Kremlin-Bicêtre, France
Institut Coeur Poumon
🇫🇷Lille, France
CHU de Montpellier
🇫🇷Montpellier, France
Hôpital Pasteur
🇫🇷Nice, France
CHU de Poitiers
🇫🇷Poitiers, France
Hôpitaux Universitaires de Strasbourg
🇫🇷Strasbourg, France
Centre Hospitalier Universitaire - Hôpital d´Adultes de Brabois
🇫🇷Vandœuvre-lès-Nancy, France
DRK Kliniken Berlin Westend
🇩🇪Berlin, Germany
Universitatsklinikum Dresden, Medizinische Klinik / Pneumologisches Studiensekretariat
🇩🇪Dresden, Germany
Universitatsklinikum Giessen und Marburg GmbH Zentrum fur Innere Medizin, Med. Klinik und Poliklinik II Studienambulanz fur Pulmonale Hypertonie
🇩🇪Gießen, Germany
Universitätsklinikum Greifswald Klinik und Poliklinik für Innere Medizin B
🇩🇪Greifswald, Germany
Universitätsklinikum Halle (Saale) / Martin-Luther-Universität Halle- Wittenberg, Universitätsklinik und Poliklinik für Innere Medizin I
🇩🇪Halle, Germany
Universitätsklinikum Hamburg-Eppendorf Zentrum für Onkologie Studienzentrum Pneumologie
🇩🇪Hamburg, Germany
Medizinische Hochschule Hannover Klinik für Pneumologie und Infektiologie
🇩🇪Hannover, Germany
Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg Zentrum für pulmonale Hypertonie
🇩🇪Heidelberg, Germany
Universitätsklinikum des Saarlandes, Innere Medizin V - Pneumologie, Allergologie, Beatmungs- und Umweltmedizin
🇩🇪Homburg, Germany
Zentrum fur Pulmona le Hypertonie, Klini k Ill fur lnnere Medizin (Kardiologie, Pneumologie, lnternlstische lntensiv medizin), Herzzentrum der Universitat zu Koln
🇩🇪Koln, Germany
Krankenhaus Neuwittelsbach
🇩🇪Munich, Germany
Klinikum der LMU Medizinische Klinik und Poliklinik V
🇩🇪München, Germany
Klinikum Wurzburg Mitte gGmbH Medizinische Klinik mit Schwerpunkt Pneumologie und Beatmungsmedizin
🇩🇪Würzburg, Germany
"Evangelismos" General Hospital, 1st Department of Clinical Care & Pulmonary Hypertension Clinic
🇬🇷Athens, Greece
ATTIKON University Hospital, 2nd Critical Care Department
🇬🇷Athens, Greece
Onassis Cardiac Surgery Center
🇬🇷Kallithéa, Greece
AHEPA University General Hospital of Thessaloniki, 1st Cardiology Clinic
🇬🇷Thessaloníki, Greece
Mater Misericordiae University Hospital, Respiratory Department
🇮🇪Dublin, Ireland
Lady Davis Carmel Medical Center
🇮🇱Haifa, Israel
Meir Medical Center
🇮🇱Kfar Saba, Israel
Rabin Medical Center
🇮🇱Petach Tikva, Israel
The Chaim Sheba Medical Center
🇮🇱Ramat Gan, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
IRCCS Azienda Ospedaliero Universitaria Di Bologna Policlinico 5 Orsola Malpighi - U.O.C. Cardiologia
🇮🇹Bologna, Italy
IRCCS Ospedale Policlinico San Martino - Cardiovascular Diseases Unit - Cardiac, Thoracic and Vascular Department
🇮🇹Genova, Italy
Azienda Ospedaliera Dei Colli - Ospedale Monaldi Centro per la Diagnosi e Terapia dell'Ipertensione Polmonare
🇮🇹Napoli, Italy
Fondazione IRCCS Policlinico San Matteo - U.O. di Cardiologia
🇮🇹Pavia, Italy
Azienda Ospealiero Universitaria Policlinico Umberto I - Dipartamento di Scienze Cliniche Internistiche Anestesiologiche e Cardiovascolari - VIII Padglione
🇮🇹Rome, Italy
Azienda Sanitaria Universitaria Giuliano Isontina /ASUGI - Ospedale di Cattinara - Cardiovascular Department Coronary Intensive Care Unit
🇮🇹Trieste, Italy
Kyushu University Hospital
🇯🇵Fukuoka, Japan
Kurume University Hospital
🇯🇵Kurume, Japan
Nagoya University Hospital
🇯🇵Nagoya-Shi, Japan
NHO Okayama Medical Center
🇯🇵Okayama, Japan
Keio University Hospital
🇯🇵Shinjuku-Ku, Japan
National Cerebral and Cardiovascular Center
🇯🇵Suita, Japan
Kyorin University Hospital
🇯🇵Tokyo, Japan
University of Tokyo Hospital
🇯🇵Tokyo, Japan
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital, Yonsei University Health System Seoul
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea, Seoul St. Mary´s Hospital
🇰🇷Seoul, Korea, Republic of
Pauls Stradins Clinical University Hospital
🇱🇻Riga, Latvia
Hospital of Lithuanian University of Health Sciences Kauno klinikos
🇱🇹Kaunas, Lithuania
Instituto nacional de Cardiologia Ignacio Chavez
🇲🇽Mexico City, Mexico
Hospital Universitario Dr. José Eleuterio González Centro de Prevención y Rehabilitación de Enfermedades Pulmonares Crónicas
🇲🇽Monterrey, Mexico
Unidad de Investigacion Clinica en Medicina, S.C.
🇲🇽Monterrey, Mexico
Amsterdam UMC, location VUmc
🇳🇱Amsterdam, Netherlands
Erasmus MC
🇳🇱Rotterdam, Netherlands
Krakowski Szpital Specjalistyczny Im. Św. Jana Pawła II Oddział Kliniczny Chorób Serca i Naczyń z Pododdziałem Intensywnego Nadzoru Kardiologicznego
🇵🇱Kraków, Poland
Europejskie Centrum Zdrowia Otwock Sp. z o.o. Szpital irn. Fryderyka Chopina Oddzial Kardiologiczny
🇵🇱Otwock, Poland
Centro Hospitalar e Universitário de Coimbra
🇵🇹Coimbra, Portugal
Centro Hospitalar Universitário Lisboa Norte, EPE - Hospital Pulido Valente
🇵🇹Lisboa, Portugal
Centro Hospitalar Universitário de Santo António
🇵🇹Porto, Portugal
Centro Hospitalar Vila Nova De Gaia
🇵🇹Vila Nova De Gaia, Portugal
CardioPulmonary Research Center
🇵🇷Guaynabo, Puerto Rico
Emergency Institute of Cardiovascular Diseases "Prof. Dr. C.C. Iliescu" Bucharest, Cardiology 2
🇷🇴Bucharest, Romania
"Niculae Stanciolu" Emergency Heart Institute for Cardivascular Diseases
🇷🇴Cluj-Napoca, Romania
Mediprax Centrum S.R.L
🇷🇴Cluj-Napoca, Romania
Targu-Mures Emergency Clinical County Hospital, Internal Medicine II
🇷🇴Târgu-Mureş, Romania
King Fahad Medical City
🇸🇦Riyadh, Saudi Arabia
King Faisal Specialist Hospital and Research Center
🇸🇦Riyadh, Saudi Arabia
Institute for Cardiovascular Diseases "Dedinje" Clinic for Cardiology
🇷🇸Belgrade, Serbia
University Clinical Centre of Serbia, Cardiology Clinic
🇷🇸Belgrade, Serbia
National Heart Centre Singapore
🇸🇬Singapore, Singapore
National University Heart Centre Singapore
🇸🇬Singapore, Singapore
Hospital Clinic I Provincial
🇪🇸Barcelona, Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Universitario 12 De Octubre
🇪🇸Madrid, Spain
Hospital Universitario Puerta De Hierro Majadahonda
🇪🇸Majadahonda, Spain
Hospital Costa del Sol
🇪🇸Marbella, Spain
Hospital Universitario Son Espases
🇪🇸Palma De Mallorca, Spain
Hospital Universitario de Salamanca (Complejo Asistencial Universitario De Salamanca)
🇪🇸Salamanca, Spain
Hospital Universitario Marques de Valdecilla
🇪🇸Santander, Spain
Hospital Universitario Virgen del Rocío
🇪🇸Sevilla, Spain
Hospital Universitario de Toledo
🇪🇸Toledo, Spain
Hospital universitario Y Politecnico La Fe
🇪🇸Valencia, Spain
Royal Papworth Hospital NHS Foundation Trust
🇬🇧Cambridge, United Kingdom
Golden Jubilee National Hospital, Agamemnon Street
🇬🇧Clydebank, United Kingdom
Hammersmith Hospital
🇬🇧London, United Kingdom
Royal Brompton Hospital, Pulmonary Hypertension Service, Sydney Street
🇬🇧London, United Kingdom
Royal Free Hospital
🇬🇧London, United Kingdom
Freeman Hospital
🇬🇧Newcastle, United Kingdom
Sheffield Clinical Research Facility, Royal Hallamshire Hospital
🇬🇧Sheffield, United Kingdom